Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently participating in study VX17-659-105 (NCT03447262)~Exclusion Criteria:~* History of drug intolerance in study VX17-659-105 that would pose an additional risk to the participant in the opinion of the investigator~* Current participation in an investigational drug trial (other than study VX17-659-105)~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Part A: Participants received ELX 200 milligram (mg) once daily (qd),TEZ 100 mg qd, and IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks.~Part B: Participants from certain countries participated in Part B and continued to received ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).